Observe Medical ASA · OSL:OBSRV
Observe Medical ASA — Q2 2021 Earnings Presentation
35 slides from Observe Medical ASA's earnings presentation, Aug 20, 2021
Slide 1: Q2 and H1 presentation 2021
OBSERVE MEDICAL Q2 and H1 presentation 2021 CEO Björn Larsson / CFO Per Arne Nygård Oslo, August 20, 2021
Slide 2: Nordic based medtech company with global reach
OBSERVE MEDICAL Nordic based medtech company with global reach Solid platform for growth, commercializing proprietary innovative medtech products on a global market – by organic growth and targeted M&A Sales through Nordic direct sales operations and international distributor and partner network Com
Slide 3: Highlights 2021
OBSERVE MEDICAL Highlights 2021 Revenues of MNOK 12.8 New distributor agreement New clinical study started by Nya through strong sales for signed for Sippi® launch in Karolinska Hospital – broadening Nordic portfolio Poland and Romania Sippi® scope of use Health Economics work strongly Global patent
Slide 4: Sippi® – the first automated digital urine meter with biofilm control
Sippi® – the first automated digital urine meter with biofilm control
Slide 5: Slide 5
Slide 6: The burden of current clinical practice / Sippi® addresses the clinical challenges
BL reshape >> intutitive The burden of current clinical practice Sippi® addresses the clinical challenges Only automated, digital urine meter with wireless data Hourly urine monitoring of patients is one of the last transfer (Sipplink®) and which detects (Sippsense®) and remaining manual monitoring
Slide 7: Addressing a significant market with strong volume growth and value opportunity
Addressing a significant market with strong volume growth and value opportunity for Sippi® Current market Market growth and Sippi® value potential accentuated by market trends and Covid pandemic CURRENT MARKET POTENTIAL ICU –RELATED CAPABILITIES VOLUME SIPPI® VALUE FURTHER ACCENTUATED GROWTH 4 bn NO
Slide 8: Sippi® implementation in hospitals
Sippi® implementation in hospitals Start with ICU, with subsequent back-/forward integration Actual example: Thoracic ICU in university hospital, Sweden* Patient flow through hospital departments Sippi® follows patient – use and volumes through implementation phases** 8 beds: ICU 10 BU, 50 DU Hospit
Slide 9: Nya Karolinska Hospital has started a new clinical study with Sippi®
Nya Karolinska Hospital has started a new clinical study with Sippi® including Acute Kidney Injury New clinical study aims to broaden Building on Sippi® clinical scope of use, including previous research: Acute Kidney Injury (AKI) “[Sippi®] … a new capacitance-based * Acute Kidney Injury (AKI) autom
Slide 10: Sippi® pricing roadmap and ambitions
Sippi® pricing roadmap and ambitions From initial rollout towards value-based pricing Value-based pricing Market adoption Share of Sippi® customer value Rollout Get Sippi® in clinical use Build further value evidence required for value-based pricing Build value evidence and test in market
Slide 11: Sippi® value built-up
Sippi® pricing roadmap and ambitions Transforming clinical evidence to economic value Cost of clinical problem Impact of Sippi® Sippi® value supporting evidence 2.5 million hospital acquired infections in Limiting risk due to less Indirect published data EU annually – 200,000 patients die* direct pa
Slide 12: Sippi® pricing roadmap and ambitions
Sippi® pricing roadmap and ambitions From initial rollout towards value-based pricing Value-based pricing Market adoption Share of Sippi® customer value Rollout Get Sippi® in clinical use Build further value evidence required for value-based pricing Build value evidence and test in market Sippi® val
Slide 13: Strong Nordic portfolio sales and increased ambition
NORDIC SALES OPERATIONS Strong Nordic portfolio sales and increased ambition Further strengthening direct sales access for Sippi® Medtech portfolio of devices Increased and disposables within ambition Urine measurement NOK 100M annual revenues* +40% gross margin Anesthesia / ICU Strong sales perform
Slide 14: Signed distribution agreement for Sippi® launch in Poland and Romania
Signed distribution agreement for Sippi® launch in Poland and Romania – and first order placed Distribution agreement Market size1 signed in June, during visit to Skamex in Poland, including visits to key Poland and Romania in total approx. 6,800 ICU beds hospitals (Poland ~3,800, Romania ~3,000) Sk
Slide 15: Financial Review
FINANCIAL REVIEW CFO Per Arne Nygård
Slide 16: Revenue and Gross Results Q2 and first half year 2021
FINANCIAL REVIEW Revenue and Gross Results Q2 and first half year 2021 Q2 Revenues and Gross Result (Amounts in TNOK) • Total revenues at TNOK 9 737, Revenue and gross results Q2 Revenue and gross results H1 driven by strong sales growth in the Nordic portfolio 12 846 9 737 Revenue breakdown by cate
Slide 17: Key Figures - Profit and Loss Statement
FINANCIAL REVIEW Key Figures - Profit and Loss Statement Q2 2021 • Significantly increased operating revenues and gross result in Q2 2021 compared to Amounts in NOK thousand (excl. earnings per share) Q2 2021 Q2 2020 H1 2021 H1 2020 FY 2020 last year. The positive change due to acquisition of the No
Slide 18: Key Figures - Statement of Financial Position
FINANCIAL REVIEW Key Figures - Statement of Financial Position Non-current assets mainly consist of goodwill and intangible assets related to Sippi®. (Amounts in TNOK) At 30 June 2021 At 30 June 2020 At 31 December 2020 ASSETS Tangible assets consist of ordinary office equipment and Right of use Non
Slide 19: Key Figures - Statement of Financial Position
FINANCIAL REVIEW Key Figures - Statement of Financial Position Equity ratio at 14.4% (Amounts in TNOK) At 30 June 2021 At 30 June 2020 At 31 December 2020 Decreased contingent considerations due to the EQUITY AND LIABILITIES Covid-19 situation which causes delays in the estimated revenue Total equit
Slide 20: Key Figures - Cash Flow Statement H1 2021
FINANCIAL REVIEW Key Figures - Cash Flow Statement H1 2021 Cash flow used in operating activities mainly related to the (Amount in TNOK) result in the period affected by increased headcount and higher activity within sales and business development Cash flow used in investing activities is mainly rel
Slide 21: Summary and Outlook
SUMMARY AND OUTLOOK CEO Björn Larsson
Slide 22: Summary & outlook
OBSERVE MEDICAL Summary & outlook New distributor agreement Outlook Agreement for Sippi® launch in Poland and Romania – and first order placed Continuous roll-out of Sippi® systems New clinical study started by Nya Karolinska Hospital Study broadening Sippi® scope of use – including Acute Kidney Inj
Slide 23: Q&A
Q&A
Slide 24: Thank you!
Thank you!
Slide 25: Appendix
Appendix
Slide 26: Finance calendar 2021
OBSERVE MEDICAL Finance calendar 2021 20 August Presentation of Q2 and first half year 2021 3 November Presentation of Q3 2021
Slide 27: Management team and board
OBSERVE MEDICAL Management team and board Management team Björn Larsson Per Arne Nygård Mikael Löfgren Anders Nachtweij Chief Executive Officer Chief Financial Officer CTO/COO Sales Director Board of directors Terje Bakken Sanna Rydberg Kathrine Gamborg Andreassen Thomas Grünfeld Chairman of the Boa
Slide 28: Condensed Consolidated Statement of Comprehensive Income
(UNAUDITED FOR THE PERIOD ENDED 30 JUNE) Condensed Consolidated Statement of Comprehensive Income (Amounts in NOK) Q2 2021 Q2 2020 H1 2021 H1 2020 FY 2020 Operating revenues 9 736 699 0 12 846 204 32 220 2 961 334 Cost of materials 5 798 629 61 945 8 064 013 121 265 1 975 121 Gross result 3 938 070
Slide 29: Condensed Consolidated Statement of Financial Position
(UNAUDITED FOR THE PERIOD ENDED 30 JUNE 2021) Condensed Consolidated Statement of Financial Position (Amounts in TNOK) At 30 June 2021 At 30 June 2020 At 31 December 2020 ASSETS Non-current assets Goodwill 34 965 33 405 36 268 Intangible assets 20 265 21 976 20 965 Tangible assets 1 849 82 703 Total
Slide 30: Condensed Consolidated Statement of Financial Positions
(UNAUDITED FOR THE PERIOD ENDED 30 JUNE 2021) Condensed Consolidated Statement of Financial Positions (Amounts in TNOK) At 30 June 2021 At 30 June 2020 At 31 December 2020 EQUITY AND LIABILITIES Total equity 11 800 5 899 20 349 Non-current liabilities Non-current lease liabilities 1 033 34 260 Conti
Slide 31: Cash Flow Statement
(UNAUDITED FOR THE PERIOD ENDED 30 JUNE 2021) Cash Flow Statement (Amounts in NOK) Q2 2021 Q2 2020 H1 2021 H1 2020 FY 2020 Cash flow from operating activities Result before tax 1 335 230 -10 143 091 -3 483 569 -10 567 034 -36 868 470 Depreciation and impairment 818 738 818 297 1 616 375 1 596 875 3
Slide 32: Top 20 Shareholders
AS OF AUGUST 3, 2021 Top 20 Shareholders Name Number of shares % of top 20 % of total Country 1 NAVAMEDIC ASA 4 222 727 25,17 % 21,54 % Norway 2 INGERØ REITEN INVESTMENT COMPANY A 3 939 394 23,48 % 20,09 % Norway 3 RO, LARS 1 501 051 8,95 % 7,66 % Norway 4 UBS Switzerland AG 1 417 522 8,45 % 7,23 %
Slide 33: Definitions of Alternative Performance Measures (APM)
OBSERVE MEDICAL Definitions of Alternative Performance Measures (APM) The APMs are regularly reviewed by management and their aim is to enhance stakeholders’ understanding of the company’s performance. APMs presented may be determined or calculated differently by other companies. Gross result: Opera
Slide 34: Copyright and Disclaimer
OBSERVE MEDICAL Copyright and Disclaimer Copyright Disclaimer reliability or completeness of the Copyright of all published material This Presentation includes and is based, Presentation, and neither Observe Medical including photographs, drawings inter alia, on forward-looking information ASA nor a
Slide 35: oKeonserve
oKeonserve Taaexe |(er=l|